Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide
Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024
Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024
DSP-5336, an Investigational Menin and Mixed-lineage Leukemia Inhibitor, is Being Evaluated in Patients with Relapsed or Refractory Acute Leukemia
Lenire is the first and only bimodal neuromodulation device to be awarded a Federal Supply Schedule (FSS) Contract from the US Government
Department presents a detailed overview of the Pharma and MediTechsector and gives a detailed presentation on the activities of Department
Augtyro is the only FDA-approved treatment option for NTRK-positive tumors studied in both TKI-naïve and TKI-pretreated patients across solid tumors
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes
Co-founder and previous CEO Lowry Curley becomes Chief Scientific Officer
The primary endpoint in the final analysis was assessed by change in the North Star Ambulatory Assessment at one year after treatment
Abbott's first-of-its-kind i2i technology enables synchronized communication between two leadless pacemakers
Subscribe To Our Newsletter & Stay Updated